256 related articles for article (PubMed ID: 25003536)
1. Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.
Rapisuwon S; Parks K; Al-Refaie W; Atkins MB
Melanoma Res; 2014 Oct; 24(5):509-11. PubMed ID: 25003536
[TBL] [Abstract][Full Text] [Related]
2. Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
Satzger I; Küttler U; Völker B; Schenck F; Kapp A; Gutzmer R
Dermatology; 2010; 220(1):77-81. PubMed ID: 19996579
[TBL] [Abstract][Full Text] [Related]
3. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
Hodi FS; Corless CL; Giobbie-Hurder A; Fletcher JA; Zhu M; Marino-Enriquez A; Friedlander P; Gonzalez R; Weber JS; Gajewski TF; O'Day SJ; Kim KB; Lawrence D; Flaherty KT; Luke JJ; Collichio FA; Ernstoff MS; Heinrich MC; Beadling C; Zukotynski KA; Yap JT; Van den Abbeele AD; Demetri GD; Fisher DE
J Clin Oncol; 2013 Sep; 31(26):3182-90. PubMed ID: 23775962
[TBL] [Abstract][Full Text] [Related]
4. KIT as a therapeutic target in metastatic melanoma.
Carvajal RD; Antonescu CR; Wolchok JD; Chapman PB; Roman RA; Teitcher J; Panageas KS; Busam KJ; Chmielowski B; Lutzky J; Pavlick AC; Fusco A; Cane L; Takebe N; Vemula S; Bouvier N; Bastian BC; Schwartz GK
JAMA; 2011 Jun; 305(22):2327-34. PubMed ID: 21642685
[TBL] [Abstract][Full Text] [Related]
5. Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma.
Zukotynski K; Yap JT; Giobbie-Hurder A; Weber J; Gonzalez R; Gajewski TF; O'Day S; Kim K; Hodi FS; Van den Abbeele AD
Cancer Imaging; 2014 Nov; 14(1):30. PubMed ID: 25609545
[TBL] [Abstract][Full Text] [Related]
6. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
Lee JH; Kim Y; Choi JW; Kim YS
J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
[TBL] [Abstract][Full Text] [Related]
7. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.
Handolias D; Hamilton AL; Salemi R; Tan A; Moodie K; Kerr L; Dobrovic A; McArthur GA
Br J Cancer; 2010 Apr; 102(8):1219-23. PubMed ID: 20372153
[TBL] [Abstract][Full Text] [Related]
8. Imatinib targeting of KIT-mutant oncoprotein in melanoma.
Jiang X; Zhou J; Yuen NK; Corless CL; Heinrich MC; Fletcher JA; Demetri GD; Widlund HR; Fisher DE; Hodi FS
Clin Cancer Res; 2008 Dec; 14(23):7726-32. PubMed ID: 19047099
[TBL] [Abstract][Full Text] [Related]
9. Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene.
Terheyden P; Houben R; Pajouh P; Thorns C; Zillikens D; Becker JC
J Invest Dermatol; 2010 Jan; 130(1):314-6. PubMed ID: 19812602
[No Abstract] [Full Text] [Related]
10. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.
Guo J; Si L; Kong Y; Flaherty KT; Xu X; Zhu Y; Corless CL; Li L; Li H; Sheng X; Cui C; Chi Z; Li S; Han M; Mao L; Lin X; Du N; Zhang X; Li J; Wang B; Qin S
J Clin Oncol; 2011 Jul; 29(21):2904-9. PubMed ID: 21690468
[TBL] [Abstract][Full Text] [Related]
11. KIT mutations in a series of melanomas and their impact on treatment with imatinib.
Botella-Estrada R; Soriano V; Rubio L; Nagore E
Actas Dermosifiliogr; 2012 Nov; 103(9):838-40. PubMed ID: 22795573
[No Abstract] [Full Text] [Related]
12. Tumour heterogeneity of mucosal melanomas during treatment with imatinib.
Schoenewolf NL; Urosevic-Maiwald M; Dummer R
Br J Dermatol; 2011 Aug; 165(2):419-24. PubMed ID: 21495997
[TBL] [Abstract][Full Text] [Related]
13. Somatic activation of KIT in distinct subtypes of melanoma.
Curtin JA; Busam K; Pinkel D; Bastian BC
J Clin Oncol; 2006 Sep; 24(26):4340-6. PubMed ID: 16908931
[TBL] [Abstract][Full Text] [Related]
14. Complete response in a melanoma patient treated with imatinib.
Brown MC; Casasola RJ
J Laryngol Otol; 2012 Jun; 126(6):638-40. PubMed ID: 22643209
[TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal stromal tumors with KIT exon 9 mutations: Update on genotype-phenotype correlation and validation of a high-resolution melting assay for mutational testing.
Künstlinger H; Huss S; Merkelbach-Bruse S; Binot E; Kleine MA; Loeser H; Mittler J; Hartmann W; Hohenberger P; Reichardt P; Büttner R; Wardelmann E; Schildhaus HU
Am J Surg Pathol; 2013 Nov; 37(11):1648-59. PubMed ID: 24061512
[TBL] [Abstract][Full Text] [Related]
16. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.
Künstlinger H; Binot E; Merkelbach-Bruse S; Huss S; Wardelmann E; Buettner R; Schildhaus HU
Hum Pathol; 2014 Mar; 45(3):573-82. PubMed ID: 24444465
[TBL] [Abstract][Full Text] [Related]
17. KIT gene mutation analysis in solid tumours: biology, clincial applications and trends in diagnostic reporting.
Tay CM; Ong CW; Lee VK; Pang B
Pathology; 2013 Feb; 45(2):127-37. PubMed ID: 23277171
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate.
Hofmann UB; Kauczok-Vetter CS; Houben R; Becker JC
Clin Cancer Res; 2009 Jan; 15(1):324-9. PubMed ID: 19118061
[TBL] [Abstract][Full Text] [Related]
19. A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib.
Allegra M; Giacchero D; Segalen C; Dumaz N; Butori C; Hofman V; Hofman P; Lacour JP; Bertolotto C; Bahadoran P; Ballotti R
J Invest Dermatol; 2014 May; 134(5):1473-1476. PubMed ID: 24317392
[No Abstract] [Full Text] [Related]
20. Another option in our KIT of effective therapies for advanced melanoma.
Carvajal RD
J Clin Oncol; 2013 Sep; 31(26):3173-5. PubMed ID: 23940226
[No Abstract] [Full Text] [Related]
[Next] [New Search]
